• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Potential for targeted therapy of eIF2, a PKR-related molecule involved in carcinogenesis and progression of hepatocellular carcinoma.

Research Project

Project/Area Number 21K08008
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 53010:Gastroenterology-related
Research InstitutionEhime University

Principal Investigator

Hiasa Yoichi  愛媛大学, 医学系研究科, 教授 (70314961)

Project Period (FY) 2021-04-01 – 2024-03-31
Project Status Completed (Fiscal Year 2023)
Budget Amount *help
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2021: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
KeywordsProtein kinase R / eIF2 / eIF2-alpha / eIF2-beta / eIF2-gamma / Hepatocellular carcinoma / Tumor proliferation / Apoptosis / PKR / PERK / 肝細胞癌 / eIF2B / protein kinase R / hepatocellular carcinoma
Outline of Research at the Start

肝細胞がんは死亡数が多く、治療が難しいがんとして知られている。肝細胞がんではウイルス感染を防ぐ役割をもつPKR蛋白が高発現している。しかし、PKRによりリン酸化されることで働きが抑制されるとされるeIF2の役割はよくわかっていない。eIF2は蛋白合成に関わることから、肝細胞がんでのこの分子の役割を明らかにするとともに、肝細胞がんの増殖の抑制、がん抑制治療の標的分子としての可能性について研究する。

Outline of Final Research Achievements

Protein kinase R (PKR) is known to be overexpressed and contribute to proliferation of hepatocellular carcinoma (HCC). In this study, I focused on eIF2, a translation initiation factor as a PKR-related molecule. In HCC patients with high expression of eIF2, had a poorer prognosis than those with low expression. In addition, the knockdown of eIF2 reduced the proliferative potential of HCC. The eIF2 is consisted by three subunits, and we revealed that the effect of each subunit on HCC was different. The eIF2α is well known to be associated with repression of RNA translation and apoptosis. However, the changes of eIF2β and eIF2γ, whose functions have not yet been clarified, had a greater impact on the progression of HCC compared to eIF2α. This study suggests that regulation of eIF2β and eIF2γ in the PKR-eIF2 pathway, would have some potentials as target therapies against HCC.

Academic Significance and Societal Importance of the Research Achievements

本研究ではPKR関連分子であるeIF2が肝細胞がんの予後に影響していることを明らかにした。
PKRをはじめとする上流シグナルによってeIF2αがリン酸化されることは知られているが、肝細胞がんにおいてPKR-eIF2α経路が発がんまたはがんの進展に及ぼす影響は明らかでない。本研究では、未だ作用について不明な点の多いeIF2βとeIF2γの発現抑制が腫瘍増殖能を抑制することを見出した。
翻訳開始因子であるeIF2の制御機序の解明は、肝細胞がんのみならず、様々な悪性腫瘍の分子標的治療に結び付く可能性がある。

Report

(4 results)
  • 2023 Annual Research Report   Final Research Report ( PDF )
  • 2022 Research-status Report
  • 2021 Research-status Report
  • Research Products

    (46 results)

All 2024 2023 2022 2021

All Journal Article (38 results) (of which Int'l Joint Research: 3 results,  Peer Reviewed: 38 results,  Open Access: 19 results) Presentation (5 results) (of which Int'l Joint Research: 2 results) Book (3 results)

  • [Journal Article] C16, a PKR inhibitor, suppresses cell proliferation by regulating the cell cycle via p21 in colorectal cancer2024

    • Author(s)
      Hashimoto Yu、Tokumoto Yoshio、Hiasa Yoichi、et al.
    • Journal Title

      Scientific Reports

      Volume: 14 Issue: 1 Pages: 9029-9029

    • DOI

      10.1038/s41598-024-59671-7

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Simple Scoring System for Esophagogastric Varices Prediction in Hepatocellular Carcinoma Patients without Liver Stiffness Evaluation2023

    • Author(s)
      Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
    • Journal Title

      Oncology

      Volume: 102 Issue: 4 Pages: 291-298

    • DOI

      10.1159/000533672

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Survival Improvements in Advanced Hepatocellular Carcinoma with Sequential Therapy by Era2023

    • Author(s)
      Nakamura Yoshiko、Hirooka Masashi、Hiraoka Atsushi、Koizumi Yohei、Yano Ryo、Morita Makoto、Okazaki Yuki、Imai Yusuke、Ohama Hideko、Hirooka Kana、Watanabe Takao、Tada Fujimasa、Yoshida Osamu、Tokumoto Yoshio、Abe Masanori、Hiasa Yoichi
    • Journal Title

      Cancers

      Volume: 15 Issue: 21 Pages: 5298-5298

    • DOI

      10.3390/cancers15215298

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Usefulness of aMAP Risk Score for Predicting Recurrence after Curative Treatment for Hepatocellular Carcinoma within Milan Criteria2023

    • Author(s)
      Ohama Hideko、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Oncology

      Volume: 101 Issue: 9 Pages: 575-583

    • DOI

      10.1159/000530987

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function2023

    • Author(s)
      Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al.
    • Journal Title

      Oncology

      Volume: 101 Issue: 10 Pages: 624-633

    • DOI

      10.1159/000531316

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Geriatric nutritional risk index as an easy‐to‐use assessment tool for nutritional status in hepatocellular carcinoma treated with atezolizumab plus bevacizumab2023

    • Author(s)
      Hiraoka Atsushi、Kumada Takashi、Hiasa Yoichi、et al.
    • Journal Title

      Hepatology Research

      Volume: 53 Issue: 10 Pages: 1031-1042

    • DOI

      10.1111/hepr.13934

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals2023

    • Author(s)
      Watanabe Takao、Tokumoto Yoshio、Hiasa Yoichi、et al.
    • Journal Title

      Scientific Reports

      Volume: 13 Issue: 1 Pages: 8992-8992

    • DOI

      10.1038/s41598-023-36052-0

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients2023

    • Author(s)
      Rimini M, Persano M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Presa J, Salani F, Lonardi S, Piscaglia F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Schirripa M, Montes M, Vivaldi C, Solda C, Hiraoka A, Sho T, Niizeki T, Nishida N, et al.
    • Journal Title

      Journal of Cancer Research and Clinical Oncology

      Volume: ー Issue: 10 Pages: 7565-7577

    • DOI

      10.1007/s00432-023-04678-2

    • Related Report
      2023 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Cancer Medicine

      Volume: 11 Issue: 20 Pages: 3796-3808

    • DOI

      10.1002/cam4.4763

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Does first‐line treatment have prognostic impact for unresectable HCC? -Atezolizumab plus bevacizumab versus lenvatinib2022

    • Author(s)
      Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al.
    • Journal Title

      Cancer Medicine

      Volume: 12 Issue: 1 Pages: 325-334

    • DOI

      10.1002/cam4.4854

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population.2022

    • Author(s)
      Casadei-Gardini A, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Cheon J, Finkelmeier F, Lim HY, Rimassa L, Presa J, Masi G, Yoo C, Lonardi S, Tovoli F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Pressiani T, Montes M, Vivaldi C, Solda C, Piscaglia F, Hiraoka A, Nishida N, et al.
    • Journal Title

      European journal of cancer

      Volume: 180 Pages: 9-20

    • DOI

      10.1016/j.ejca.2022.11.017

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice2022

    • Author(s)
      Tanaka Takaaki、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al.
    • Journal Title

      Hepatology Research

      Volume: 52 Issue: 9 Pages: 773-783

    • DOI

      10.1111/hepr.13797

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Scientific Reports

      Volume: 12 Issue: 1 Pages: 8421-8421

    • DOI

      10.1038/s41598-022-12058-y

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Clinical Usefulness of Surgical Resection Including the Complementary Use of Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma2022

    • Author(s)
      Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
    • Journal Title

      Cancers

      Volume: 15 Issue: 1 Pages: 236-236

    • DOI

      10.3390/cancers15010236

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Glasgow prognostic score predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib: a multicenter analysis2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      European Journal of Gastroenterology and Hepatology

      Volume: 34 Issue: 8 Pages: 857-864

    • DOI

      10.1097/meg.0000000000002398

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Clinical Predictor of Urinary Protein as Adverse Event Associated with Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma2022

    • Author(s)
      Hiraoka Atsushi、Kumada Takashi、Tada Toshifumi、Hiasa Yoichi、et al.
    • Journal Title

      Oncology

      Volume: 100 Issue: 12 Pages: 645-654

    • DOI

      10.1159/000526521

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis2022

    • Author(s)
      Hatanaka Takeshi、Hiraoka Atsushi、Tada Toshifumi、Hiasa Yoichi、et al.
    • Journal Title

      Hepatology Research

      Volume: 52 Issue: 5 Pages: 462-470

    • DOI

      10.1111/hepr.13748

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      European Journal of Gastroenterology and Hepatology

      Volume: 34 Issue: 6 Pages: 698-706

    • DOI

      10.1097/meg.0000000000002356

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study2022

    • Author(s)
      Liu Chuan、Cao Zhujun、Yan Huadong、Hiasa Yoichi、et al.
    • Journal Title

      American Journal of Gastroenterology

      Volume: 117 Issue: 10 Pages: 1605-1613

    • DOI

      10.14309/ajg.0000000000001873

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment2022

    • Author(s)
      Ohama Hideko、Hiraoka Atsushi、Tada Fujimasa、Hiasa Yoichi、et al.
    • Journal Title

      Cancers

      Volume: 14 Issue: 22 Pages: 5524-5524

    • DOI

      10.3390/cancers14225524

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study2022

    • Author(s)
      Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Hepatology International

      Volume: 16 Issue: 5 Pages: 1150-1160

    • DOI

      10.1007/s12072-022-10358-z

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] Nutritional Status Is Associated with Prognosis in Patients with Advanced Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Oncology

      Volume: 101 Issue: 4 Pages: 270-282

    • DOI

      10.1159/000527676

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study2022

    • Author(s)
      Tada Toshifumi、Kumada Takashi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Cancer Medicine

      Volume: 12 Issue: 6 Pages: 6980-6993

    • DOI

      10.1002/cam4.5495

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study2022

    • Author(s)
      Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Cancer Medicine

      Volume: 12 Issue: 5 Pages: 5293-5303

    • DOI

      10.1002/cam4.5337

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Development and validation of a modified albumin?bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab2022

    • Author(s)
      Hatanaka Takeshi、Kakizaki Satoru、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Hepatology International

      Volume: 17 Issue: 1 Pages: 86-96

    • DOI

      10.1007/s12072-022-10406-8

    • Related Report
      2022 Research-status Report
    • Peer Reviewed
  • [Journal Article] The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis2022

    • Author(s)
      Hatanaka Takeshi、Naganuma Atsushi、Hiraoka Atsushi、Hiasa Yoichi、et al.
    • Journal Title

      Cancer Medicine

      Volume: 12 Issue: 4 Pages: 4259-4269

    • DOI

      10.1002/cam4.5294

    • Related Report
      2022 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience2022

    • Author(s)
      Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Ohama H、Nouso K、Morishita A、Tsutsui A、Nagano T、Itokawa N、Hiasa Y、Kudo M、et al.
    • Journal Title

      Cancer Reports

      Volume: 5 Issue: 2

    • DOI

      10.1002/cnr2.1464

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria ? Multicenter analysis2022

    • Author(s)
      Hiraoka A、Kumada T、Tada T、Hirooka M、Kariyama K、Tani J、Atsukawa M、Takaguchi K、Itobayashi E、Fukunishi S、Tsuji K、Ishikawa T、Tajiri K、Ochi H、Yasuda S、Toyoda H、Ogawa C、Nishimura T、Hatanaka T、Kakizaki S、Shimada N、Kawata K、Naganuma A、Tanaka T、Ohama H、Nouso K、Morishita A、Hiasa Y、Kudo M、et al.
    • Journal Title

      Hepatology Research

      Volume: 52 Issue: 3 Pages: 308-316

    • DOI

      10.1111/hepr.13734

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Identification of microRNA-96-5p as a postoperative, prognostic microRNA predictor in non-viral hepatocellular carcinoma2022

    • Author(s)
      Matsui T, Hamada TS, Naito Y, Nojima M, Iio E, Tamori A, Kubo S, Ide T, Kondo Y, Eguchi Y, Komori A, Morine Y, Shimada M, Utsunomiya T, Kimura K, Hiasa Y, Ochiya T, Naiki A, Takahashi S, Tanaka Y
    • Journal Title

      Hepatol Res.

      Volume: 52(1) Issue: 1 Pages: 93-104

    • DOI

      10.1111/hepr.13674

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Impact of modified albumin?bilirubin grade on survival in patients with HCC who received lenvatinib2021

    • Author(s)
      Tada T、Kumada T、Hiraoka A、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Tani J、Nakamura S、Nouso K、Tsutsui A、Nagano T、Takaaki T、Hiasa Y、et al.
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 14474-14474

    • DOI

      10.1038/s41598-021-93794-5

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study2021

    • Author(s)
      Rimini M、Shimose S、Lonardi S、Tada T、Masi G、Iwamoto H、Lai E、Burgio V、Hiraoka A、Ishikawa T、Solda C、Shirono T、Vivaldi C、Takaguchi K、Shimada N、Astara G、Koga H、Nouso K、Joko K、Torimura T、Hiasa Y、Salani F、Scartozzi M、Cascinu S、Casadei GA.
    • Journal Title

      Hepatology Research

      Volume: 51 Issue: 12 Pages: 1229-1241

    • DOI

      10.1111/hepr.13718

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Radiofrequency Ablation Covering the Entire Tumor Blood Drainage Area Improves Survival in Hepatocellular Carcinoma2021

    • Author(s)
      Hirooka M、Koizumi Y、Tanaka T、Sunago K、Nakamura Y、Watanabe T、Yoshida O、Tokumoto Y、Abe M、Hiasa Y.
    • Journal Title

      Hepatology Communications

      Volume: 5 Issue: 7 Pages: 1300-1309

    • DOI

      10.1002/hep4.1703

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Therapeutic efficacy of lenvatinib as third‐line treatment after regorafenib for unresectable hepatocellular carcinoma progression2021

    • Author(s)
      Hiraoka A、Kumada T、Hatanaka T、Tada T、Kariyama K、Tani J、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Ogawa C、Tamai T、Kakizaki S、Tojima H、Hiasa Y、Kudo M、et al.
    • Journal Title

      Hepatology Research

      Volume: 51 Issue: 8 Pages: 880-889

    • DOI

      10.1111/hepr.13644

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] AFP and eGFR are related to early and late recurrence of HCC following antiviral therapy.2021

    • Author(s)
      Watanabe T, Tokumoto Y, Joko K, Michitaka K, Horiike N, Tanaka Y, Tada F, Kisaka Y, Nakanishi S, Yamauchi K, Ochi H, Hiraoka A, Yagi S, Yukimoto A, Hirooka M, Abe M, Hiasa Y
    • Journal Title

      BMC Cancer

      Volume: 14;21(1) Issue: 1 Pages: 699-699

    • DOI

      10.1186/s12885-021-08401-7

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] The long noncoding RNA of RMRP is downregulated by PERK, which induces apoptosis in hepatocellular carcinoma cells2021

    • Author(s)
      Yukimoto Atsushi、Watanabe Takao、Sunago Kotaro、Nakamura Yoshiko、Tanaka Takaaki、Koizumi Yohei、Yoshida Osamu、Tokumoto Yoshio、Hirooka Masashi、Abe Masanori、Hiasa Yoichi
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 7926-7926

    • DOI

      10.1038/s41598-021-86592-6

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study2021

    • Author(s)
      Hiraoka A、Kumada T、Tada T、Tani J、Kariyama K、Fukunishi S、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Kawata K、Yasuda S、Toyoda H、Aoki T、Tanaka T、Ohama H、Hiasa Y、Kudo M、et al.
    • Journal Title

      Scientific Reports

      Volume: 11 Issue: 1 Pages: 16663-16663

    • DOI

      10.1038/s41598-021-96089-x

    • Related Report
      2021 Research-status Report
    • Peer Reviewed / Open Access
  • [Journal Article] Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib2021

    • Author(s)
      Rapposelli IG、Tada T、Shimose S、Burgio V、Kumada T、Iwamoto H、Hiraoka A、Niizeki T、Atsukawa M、Koga H、Hirooka M、Torimura T、Iavarone M、Tortora R、Campani C、Lonardi S、Tamburini E、Piscaglia F、Masi G、Cabibbo G、Giuseppe FF、Silletta M、Tsuji K、Ishikawa T、Hiasa Y、Casadei GA、et al.
    • Journal Title

      Liver International

      Volume: 41 Issue: 12 Pages: 2997-3008

    • DOI

      10.1111/liv.15014

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Journal Article] Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis2021

    • Author(s)
      Tada T、Kumada T、Hiraoka A、Michitaka K、Atsukawa M、Hirooka M、Tsuji K、Ishikawa T、Takaguchi K、Kariyama K、Itobayashi E、Tajiri K、Shimada N、Shibata H、Ochi H、Yasuda S、Toyoda H、Fukunishi S、Ohama H、Kawata K、Nakamura S、Nouso K、Tsutsui A、Nagano T、Hiasa Y、et al.
    • Journal Title

      Oncology

      Volume: 99 Issue: 8 Pages: 518-527

    • DOI

      10.1159/000515896

    • Related Report
      2021 Research-status Report
    • Peer Reviewed
  • [Presentation] C型肝硬変におけるSVR後の肝予備能と肝発癌の予測2023

    • Author(s)
      渡辺崇夫、徳本良雄一、日浅陽一
    • Organizer
      第59回日本肝臓学会総会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 門脈圧亢進症を伴った切除不能肝細胞癌患者におけるAtezolizumab+Bevacizumabの治療成績2023

    • Author(s)
      多田藤政、多田俊史、日浅陽一 他
    • Organizer
      第28回日本肝がん分子標的治療研究会
    • Related Report
      2023 Annual Research Report
  • [Presentation] 初回治療として根治術を施行した肝細胞癌患者におけるSVR時期と予後の検討2023

    • Author(s)
      多田藤政、中谷康輔、日浅陽一 他
    • Organizer
      第45回日本肝臓学会西部会
    • Related Report
      2023 Annual Research Report
  • [Presentation] Clinical usefulness of lenvatinib as second-line treatment for hepatocellular carcinoma following atezolizumab plus bevacizumab failure.2023

    • Author(s)
      Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al.
    • Organizer
      American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2023
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Atezolizumab plus bevacizumab therapy for hepatocellular carcinoma: The Geriatric Nutritional Risk Index as a convenient prognostic evaluation tool.2023

    • Author(s)
      Atsushi Hiraoka, Takashi Kumada, Yoichi Hiasa, et al.
    • Organizer
      American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2023
    • Related Report
      2023 Annual Research Report
    • Int'l Joint Research
  • [Book] 今日の治療指針 202年版: 私はこう治療している2024

    • Author(s)
      日浅陽一 (編)福井次矢、高木 誠、小室一成
    • Total Pages
      2224
    • Publisher
      医学書院
    • ISBN
      9784260053426
    • Related Report
      2023 Annual Research Report
  • [Book] 消化器内科診療Controversy2023

    • Author(s)
      廣岡昌史、日浅陽一 (編)竹原徹郎
    • Total Pages
      406
    • Publisher
      中外医学社
    • ISBN
      9784498140523
    • Related Report
      2023 Annual Research Report
  • [Book] 解剖生理からみちびく消化器ケア Q&A108: イラスト×写真で機能・検査・疾患・治療・ケアのギモンが解決!2023

    • Author(s)
      廣岡昌史、日浅陽一 (編)李 相雄
    • Total Pages
      256
    • Publisher
      メディカ出版
    • ISBN
      9784840480260
    • Related Report
      2023 Annual Research Report

URL: 

Published: 2021-04-28   Modified: 2025-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi